Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003104
Status:
COMPLETED
Last Update Posted:
2013-06-26
First Post:
1999-11-01
Brief Title:
Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase II Study Using High Dose Three Dimensional Conformal Radiation Therapy in Intermediate Prognostic Risk Patients With Adenocarcinoma of the Prostate
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiation therapy uses high-energy x-rays to kill tumor cells Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation therapy
PURPOSE This phase II trial is studying how well radiation therapy that has been planned with a computer works in treating patients with prostate cancer
PURPOSE This phase II trial is studying how well radiation therapy that has been planned with a computer works in treating patients with prostate cancer
Detailed Description:
OBJECTIVES
Establish the efficacy of high-dose three-dimensional conformal radiotherapy in patients with intermediate prognostic risk adenocarcinoma of the prostate
Determine the PSA relapse-free survival rate of this patient population
OUTLINE Patients receive high-dose three-dimensional conformal radiotherapy 4-5 days per week for at least 9 weeks
Patients are evaluated at least weekly during radiotherapy and at 2 and 4 months after treatment completion Thereafter patients are followed every 6 months for a total of 3 years
PROJECTED ACCRUAL A total of 50 patients will be accrued for this study
Establish the efficacy of high-dose three-dimensional conformal radiotherapy in patients with intermediate prognostic risk adenocarcinoma of the prostate
Determine the PSA relapse-free survival rate of this patient population
OUTLINE Patients receive high-dose three-dimensional conformal radiotherapy 4-5 days per week for at least 9 weeks
Patients are evaluated at least weekly during radiotherapy and at 2 and 4 months after treatment completion Thereafter patients are followed every 6 months for a total of 3 years
PROJECTED ACCRUAL A total of 50 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-H97-0006 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000065838 | REGISTRY | None | None |